Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.25 EUR | -0.66% | -.--% | +97.79% |
Aug. 29 | MorphoSys AG Announces Changes in the Composition of the Supervisory Board | CI |
Aug. 29 | MorphoSys AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 | CI |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 71.76M | 328M | 180M | 278M | 238M | |||||
Total Revenues | 71.76M | 328M | 180M | 278M | 238M | |||||
Cost of Goods Sold, Total | 12.09M | 9.17M | 32.19M | 48.62M | 58.35M | |||||
Gross Profit | 59.67M | 319M | 147M | 230M | 180M | |||||
Selling General & Admin Expenses, Total | 59.34M | 159M | 182M | 153M | 147M | |||||
R&D Expenses | 107M | 125M | 222M | 290M | 274M | |||||
Other Operating Expenses, Total | 166M | 285M | 404M | 442M | 421M | |||||
Operating Income | -106M | 33.98M | -256M | -212M | -241M | |||||
Interest Expense, Total | -1.73M | -28.35M | -65.82M | -117M | -110M | |||||
Interest And Investment Income | 223K | 1.23M | 723K | 4.62M | 18.32M | |||||
Net Interest Expenses | -1.5M | -27.12M | -65.1M | -112M | -91.54M | |||||
Income (Loss) On Equity Invest. | - | - | - | -4.31M | -8.17M | |||||
Currency Exchange Gains (Loss) | -180K | 65.65M | -25.82M | -34.99M | 5.89M | |||||
Other Non Operating Income (Expenses) | 1.59M | -25.27M | 8.21M | 389M | 135M | |||||
EBT, Excl. Unusual Items | -107M | 47.24M | -339M | 25.79M | -200M | |||||
Merger & Related Restructuring Charges | - | - | -19.7M | - | - | |||||
Impairment of Goodwill | - | -2.06M | -231M | - | -1.62M | |||||
Gain (Loss) On Sale Of Investments | 1.67M | -9.1M | - | - | 20.63M | |||||
Gain (Loss) On Sale Of Assets | - | 379K | - | - | - | |||||
Asset Writedown | -1.65M | -13.97M | -1.55M | -8.27M | -9.58M | |||||
EBT, Incl. Unusual Items | -107M | 22.49M | -591M | 17.52M | -191M | |||||
Income Tax Expense | -3.51M | -75.4M | -76.59M | 169M | -1.19M | |||||
Earnings From Continuing Operations | -103M | 97.89M | -514M | -151M | -190M | |||||
Net Income to Company | -103M | 97.89M | -514M | -151M | -190M | |||||
Net Income - (IS) | -103M | 97.89M | -514M | -151M | -190M | |||||
Net Income to Common Incl Extra Items | -103M | 97.89M | -514M | -151M | -190M | |||||
Net Income to Common Excl. Extra Items | -103M | 97.89M | -514M | -151M | -190M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -3.26 | 3.01 | -15.4 | -4.42 | -5.53 | |||||
Basic EPS - Continuing Operations | -3.26 | 3.01 | -15.4 | -4.42 | -5.53 | |||||
Basic Weighted Average Shares Outstanding | 31.61M | 32.53M | 33.4M | 34.16M | 34.31M | |||||
Net EPS - Diluted | -3.26 | 2.97 | -15.4 | -4.42 | -5.53 | |||||
Diluted EPS - Continuing Operations | -3.26 | 2.97 | -15.4 | -4.42 | -5.53 | |||||
Diluted Weighted Average Shares Outstanding | 31.61M | 33.17M | 33.4M | 34.16M | 34.31M | |||||
Normalized Basic EPS | -2.11 | 0.91 | -6.34 | 0.47 | -3.65 | |||||
Normalized Diluted EPS | -2.11 | 0.89 | -6.34 | 0.47 | -3.65 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | -103M | 38.69M | -250M | -206M | -235M | |||||
EBITA | -105M | 36.14M | -253M | -209M | -238M | |||||
EBIT | -106M | 33.98M | -256M | -212M | -241M | |||||
EBITDAR | -103M | 38.78M | -249M | -206M | -235M | |||||
Total Revenues (As Reported) | - | - | 180M | 278M | 238M | |||||
Effective Tax Rate - (Ratio) | 3.29 | -335.22 | 12.96 | 962.19 | 0.62 | |||||
Current Foreign Taxes | - | 67.07M | -1.17M | 577K | -1.46M | |||||
Total Current Taxes | 1K | 67.07M | -1.17M | 577K | -1.46M | |||||
Deferred Foreign Taxes | - | -142M | -75.42M | 168M | 275K | |||||
Total Deferred Taxes | -3.51M | -142M | -75.42M | 168M | 275K | |||||
Normalized Net Income | -66.59M | 29.53M | -212M | 16.12M | -125M | |||||
Interest on Long-Term Debt | 1.73M | 18.96M | 33.61M | 36.52M | 20.8M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 22.67M | 108M | 122M | 92.4M | 81.37M | |||||
General and Administrative Expenses | 36.66M | 51.4M | 58.59M | 60.14M | 65.8M | |||||
Research And Development Expense From Footnotes | 108M | 141M | 225M | 298M | 284M | |||||
Net Rental Expense, Total | 41K | 81K | 1.57M | 275K | 31K | |||||
Imputed Operating Lease Interest Expense | 26.58K | 102K | 870K | 150K | 15.42K | |||||
Imputed Operating Lease Depreciation | 14.42K | -20.83K | 700K | 125K | 15.58K | |||||
Stock-Based Comp., Other (Total) | 6.65M | 8.96M | 4.28M | 6.88M | 27.37M | |||||
Total Stock-Based Compensation | 6.65M | 8.96M | 4.28M | 6.88M | 27.37M |